Clinical trials: Pick Disease of the Brain
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Alzheimer's Tau Platform: Regimen A - AADvac1
The Alzheimer's Tau Platform (ATP) is a multi-center platform trial to evaluate the safety and effectiveness of tau-directed therapies, alone or in combination with donanemab, in adults aged 50-80 with late preclinical or early…
- Conditions
- Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease
- Trial name
- ATP (NCT07167966)
- Testing
- AADvac1, Donanemab
- Where
- 7 sites in United States
- Volunteers
- 450 people
- Sponsor
- Paul S. Aisen
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
This Phase III study is intended to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy (PSP).
- Trial name
- NCT07498426
- Testing
- NIO752
- Where
- 64 sites in United States, Australia and 10 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Progressive Supranuclear Palsy, Corticobasal Degeneration
A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies
This is a phase II study intended to evaluate the safety, tolerability and pharmacodynamics of NIO752 in participants with primary tauopathies.
- Conditions
- Progressive Supranuclear Palsy, Corticobasal Degeneration, Frontotemporal Lobar Degeneration, Tauopathies
- Trial name
- NCT07868328
- Testing
- NIO752
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer, Alzheimer Dementia (AD)
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain.
- Trial name
- LymphDAD (NCT07854327)
- Testing
- Cervical lymphovenous anastomosis (LVA)
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Siena
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's Disease Neuroimaging Initiative 4
The Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) is a non-randomized, longitudinal, natural history study designed to validate biomarkers, improve clinical trial design, and advance understanding of Alzheimer's disease…
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia
- Trial name
- ADNI4 (NCT05617014)
- Testing
- Neuraceq, Amyvid, Tauvid
- Where
- 65 sites in United States, Canada
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Insomnia
A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
The goal of this clinical trial is to explore the potential neuroprotective benefits of a dual orexin receptor antagonist (DORA) in adults with insomnia.
- Trial name
- Neuro-DORA (NCT06823752)
- Testing
- Lemborexant 10 MG
- Where
- Australia
- Volunteers
- 20 people
- Sponsor
- Woolcock Institute of Medical Research
Frontotemporal Dementia, Behavioral Variant, Alzheimer Disease
ECOCAPTURE for the Assessment of Apathy Under Real-life Conditions
ECOCAPTURE@HOME is a study which is currently being developed with the objective to capture the behavioral signature of apathy in everyday life context through remote monitoring of participants' behavior for about one month.
- Trial name
- @HOME (NCT04865172)
- Testing
- Remote collection of passive and active data for 28 consecutive days
- Where
- France
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Tauopathies, Neurodegenerative Diseases
Tau PET/CT in Various Tau-Related Disease Patients
To evaluate the potential usefulness of 18F-S16/T807 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.
- Conditions
- Tauopathies, Neurodegenerative Diseases, Neurodegeneration
- Trial name
- NCT06690983
- Testing
- 18F-S16/T807
- Where
- 3 sites in China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University
Adrenoleukodystrophy, Batten Disease
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 in patients who are undergoing standard treatment with umbilical cord blood transplant (UCBT) for inborn…
- Conditions
- Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell
- Trial name
- DUOC-01 (NCT02254863)
- Testing
- DUOC-01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Joanne Kurtzberg, MD
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 48 people
- Sponsor
- Eli Lilly and Company
Primary Progressive Aphasia
Semantic Rehabilitation for Patients With Primary Progressive Semantic Aphasia
This project aims to measure the effect of a semantic rehabilitation protocol for patients with primary progressive semantic aphasia and using the SCED methodology.
- Trial name
- SCED-APPvs (NCT04957537)
- Testing
- semantic therapy and semantic re-education
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Early Onset Alzheimer Disease, Alzheimer Disease
Longitudinal Early-onset Alzheimer's Disease Study Protocol
The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment.
- Conditions
- Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- LEADS (NCT03507257)
- Testing
- Flortaucipir, Florbetaben, Fluorodeoxyglucose
- Where
- 23 sites in United States, Argentina and 4 more
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Indiana University
Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant
Nabilone for Agitation in Frontotemporal Dementia
The primary goal of this study is to test the hypothesis that oral nabilone treatment will reduce agitation compared with placebo in patients with Frontotemporal Dementia (both behavioural variant frontotemporal dementia and…
- Conditions
- Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, Primary Progressive Aphasia, bvFTD
- Trial name
- Nabilone-FTD (NCT05742698)
- Testing
- Nabilone
- Where
- 7 sites in Canada
- Volunteers
- 3 people
- Sponsor
- Simon Ducharme, MD
Cognitively Normal Older Adults, Hypertension
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau…
- Conditions
- Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
- Trial name
- IPAT (NCT05331144)
- Testing
- Angiotensin II Receptor Blockers (ARBs, losartan) and Calcium Channel Blockers (CCB, amlodipine), PCP
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Rong Zhang
Progressive Supranuclear Palsy (PSP), Healthy Participants
First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain
This clinical study is being conducted to learn more about two new imaging drugs, called [18F]ABBV-964i and [18F]ABBV-965i, which are designed to help doctors see changes in the brain related to a condition called Progressive…
- Trial name
- NCT07348276
- Testing
- [18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Invicro
Alzheimer Disease
Learning Amyloid and Tau Results
This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to…
- Trial name
- NCT07222930
- Testing
- Disclose amyloid, tau results, Follow-up Assessments
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer Disease
A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease
- Trial name
- NCT05063539
- Testing
- LY3372689
- Where
- 69 sites in United States, Australia and 3 more
- Volunteers
- 327 people
- Sponsor
- Eli Lilly and Company
Opioid-Related Disorders
Tau PET Imaging in Opioid Use Disorder
The investigators plan to enroll up to 60 adult subjects in this study. There will be three groups of up to 20 subjects each in this study.
- Trial name
- NCT05651516
- Testing
- 18F-PI-2620 PET/CT
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Alzheimer Disease
Study of Tau Imaging With the Use of [18F]MK-6240 Tracer
The recent development of a PET tracer,[18F]MK-6240(an[18F]tau imaging agent,CerveauTechnologies)that has high affinity for the human phosphorylated tau deposits in AD brain offers new opportunities to investigate tau pathology.
- Trial name
- MKADAD (NCT04104659)
- Testing
- MK 6240
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Tammie L. S. Benzinger, MD, PhD
Frontotemporal Dementia, FTD
A Study of PBFT02 in Participants With FTD and Mutations in the Granulin Precursor (GRN) or C9ORF72 Genes
PBFT02 is a gene therapy for frontotemporal dementia intended to deliver a functional copy of the GRN gene to the brain. This study will assess the safety, tolerability and efficacy of this treatment in patients with…
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia Frontotemporal
- Trial name
- upliFT-D (NCT04747431)
- Testing
- PBFT02
- Where
- 10 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Passage Bio, Inc.